Shukui Qin

机构：Nanjing University of Chinese Medicine, China Pharmaceutical University, Nanjing General Hospital of Nanjing Military Command, 81th Hospital of PLA

发表论文 22 篇 · 总被引 110 次 · h-index 5

代表论文

• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 (2024 · Hepatology International · 被引 59)
• Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study (2025 · The Lancet Oncology · 被引 24)
• Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses. (2025 · Journal of Clinical Oncology · 被引 11)
• Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT (2024 · Liver Cancer · 被引 7)
• LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma. (2025 · Journal of Clinical Oncology · 被引 6)
• [Preparation of heat shock protein 70 (Hsp70) and idiotypic determinant single-chain antibody (Id-ScFv) in a patient with B-cell chronic lymphatic leukemia (B-CLL) and antitumor effect of peptide complex Hsp70-Id]. (2008 · PubMed · 被引 2)